Heartflow Inc Dossier
Qualitative Analysis
Business overview
Heartflow, Inc. (Nasdaq: HTFL) is a commercial-stage medical technology company specializing in artificial intelligence (AI) and cloud-based precision heart care solutions. The company's proprietary platform transforms standard coronary computed tomography angiography (CCTA) scans into personalized, dynamic 3D models of the heart to non-invasively analyze blood flow and identify blockages. Its core commercial suite, Heartflow One, consists of three FDA-cleared software products: Roadmap Analysis (for early CAD detection), FFRct Analysis (for evaluating blood flow and determining revascularization benefits), and Plaque Analysis (for quantifying and characterizing plaque composition). By replacing invasive diagnostic catheterizations with non-invasive physiologic simulations, Heartflow improves diagnostic accuracy, optimizes treatment pathways, and lowers overall healthcare costs.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating the adoption of AI-driven plaque quantification and characterization, supported by newly established Category I CPT code 75577 and expanded coverage from major national payers.
Expected impact: Projected to generate $19 million to $21 million in dedicated Plaque revenue in 2026 and drive overall gross margin expansion.
Introducing the PCI Navigator pre-procedural planning tool to the Heartflow One platform and initiating a registry to evaluate its impact on clinical strategy and procedural efficiency.
Expected impact: Establishes Heartflow as a leader in CT-guided PCI planning, bridging the gap between non-invasive diagnostics and cath lab intervention.
Relocating the corporate headquarters to San Francisco and optimizing facilities to improve operational efficiency.
Expected impact: Expected to streamline operations and align the company's cost structure with its long-term path to profitability.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Integrates the Heartflow One platform (including FFR-CT and Plaque Analysis) across CVAUSA's network of over 460 physicians and 100+ clinic locations, serving over 1.3 million patients annually.
Terms: Terms not disclosed